Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) CEO Raju Mohan acquired 238,248 shares of Ventyx Biosciences stock in a transaction on Friday, November 22nd. The shares were bought at an average cost of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the purchase, the chief executive officer now directly owns 1,913,276 shares of the company's stock, valued at $3,501,295.08. The trade was a 14.22 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Raju Mohan also recently made the following trade(s):
- On Monday, November 25th, Raju Mohan bought 261,752 shares of Ventyx Biosciences stock. The stock was bought at an average price of $2.01 per share, with a total value of $526,121.52.
Ventyx Biosciences Price Performance
VTYX stock opened at $2.06 on Tuesday. Ventyx Biosciences, Inc. has a 12 month low of $1.67 and a 12 month high of $11.48. The firm's 50-day moving average is $2.19 and its 200 day moving average is $2.64. The company has a market capitalization of $145.66 million, a PE ratio of -0.87 and a beta of 0.37.
Wall Street Analyst Weigh In
VTYX has been the topic of several recent research reports. Wells Fargo & Company decreased their price target on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating on the stock in a report on Monday, August 12th. HC Wainwright restated a "neutral" rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reiterated an "outperform" rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $10.00.
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Get Our Latest Stock Report on Ventyx Biosciences
Institutional Trading of Ventyx Biosciences
Several institutional investors and hedge funds have recently modified their holdings of VTYX. Palumbo Wealth Management LLC purchased a new position in Ventyx Biosciences during the 3rd quarter worth $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock worth $30,000 after buying an additional 5,310 shares during the period. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter worth $32,000. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences during the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after acquiring an additional 7,096 shares in the last quarter. Institutional investors own 97.88% of the company's stock.
About Ventyx Biosciences
(
Get Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
